TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30684600

Group type: EXPERIMENTAL
Intervention: Jumbo forceps polypectomy (JFP)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: JFP for polyps >3 mm
Number of subjects: 169

Group type: COMPARATOR
Intervention: CSP for polyps >3 mm
Number of subjects: 169
Study: 26588236

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/d
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 27751589

Group type: EXPERIMENTAL
Intervention: 7.5mg oral paroxetine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25043905

Group type: EXPERIMENTAL
Intervention: Playing a violent video game as a male avatar
Number of subjects: 242

Group type: COMPARATOR
Intervention: Playing a violent video game as a female avatar
Number of subjects: 242
Study: 22421064

Group type: EXPERIMENTAL
Intervention: Augmentation with olanzapine (RIS+OLZ group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Increased risperidone dose (RIS+RIS group)
Number of subjects: 26
Study: 20697290

Group type: EXPERIMENTAL
Intervention: Uncoated probiotic strains (5 x 10^9 CFU/strain/day for 21 days)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Microencapsulated probiotic strains (1 x 10^9 CFU/strain/day for 21 days)
Number of subjects: 44
Study: 18786039

Group type: EXPERIMENTAL
Intervention: Non-theory-based interventions focusing on at-risk and older children, employing intervention specialists
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Single approach interventions
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 16192774

Group type: COMPARATOR
Intervention: Intravenous treatment (lidocaine-sufentanil-clonidine)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Postoperative epidural treatment (intravenous-epidural)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Intraoperative epidural treatment (epidural-epidural and epidural-intravenous)
Number of subjects: 85
Study: 12519409

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine oestrogens
Number of subjects: 2

Group type: COMPARATOR
Intervention: Transdermal 17 beta‐oestradiol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oral 17 beta‐oestradiol followed by sequential oestrogen‐progestogen HRT (17 beta‐oestradiol and dydrogesterone)
Number of subjects: 2
Study: 10759926

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A, 100 units, diluted in 1 mL of saline
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (1 mL)
Number of subjects: 26
Study: 8641826

Group type: EXPERIMENTAL
Intervention: 200 mg of oral zinc sulfate once daily for 24 months
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo once daily for 24 months
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 1507320

Group type: EXPERIMENTAL
Intervention: 67Ga-citrate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 111In-oxine
Number of subjects: 15
Study: 30922341

Group type: EXPERIMENTAL
Intervention: Maternal health CHW program
Number of subjects: 2329

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2329
Study: 28911062

Group type: EXPERIMENTAL
Intervention: TPF-E (cisplatin and docetaxel 75mg/m2 on day 1 followed by 5-FU 750mg/m2/day as a continuous infusion on days 1-5 plus cetuximab at a loading dose of 400mg/m2 followed by a weekly dose of 250mg/m2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 40mg/m2
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Weekly carboplatin, AUC of 1.5mg/ml/min
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Radiotherapy (70Gy over 7 weeks in 2Gy fractions) with weekly cetuximab
Number of subjects: 47
Study: 26031148

Group type: EXPERIMENTAL
Intervention: Methotrexate monotherapy (5-20 mg weekly)
Number of subjects: 63
Study: 24106872

Group type: EXPERIMENTAL
Intervention: Cocaine HCl (300 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cannabis (THC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 21212421

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20152899

Group type: EXPERIMENTAL
Intervention: Matrifen (100 microg/h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Durogesic DTrans (100 microg/h)
Number of subjects: 30
Study: 17525698

Group type: EXPERIMENTAL
Intervention: Wearing a splint for 12 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Surgical release
Number of subjects: 14
Study: 15741251

Group type: EXPERIMENTAL
Intervention: Ganirelix (selective GnRH-receptor antagonist)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study: 11940323

Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty
Number of subjects: 69

Group type: COMPARATOR
Intervention: Plain old balloon angioplasty
Number of subjects: 69
Study: 9804024

Group type: EXPERIMENTAL
Intervention: Cochlear implants (CI), post-operative period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-CI group
Number of subjects: 0
Study: 7614643

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg plus sodium citrate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg plus sodium citrate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sodium citrate alone
Number of subjects: 25
Study: 2693542

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (LFLX) 600 mg/day for 5 days
Number of subjects: 169

Group type: COMPARATOR
Intervention: Pipemidic acid (PPA) 2000 mg/day for 5 days
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (LFLX)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Pipemidic acid (PPA)
Number of subjects: 169
Study: 38806

Group type: EXPERIMENTAL
Intervention: Long-term neuroleptic treatment (individually adjusted dosage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term neuroleptic treatment
Number of subjects: 0
Study: 31537559

Group type: EXPERIMENTAL
Intervention: Individualised structured cognitive rehabilitation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Best patient‐centred care for attention disorders
Number of subjects: 50
Study: 28935470

Group type: EXPERIMENTAL
Intervention: RV5 (pentavalent live human-bovine reassortant rotavirus vaccine)
Number of subjects: 4040

Group type: EXPERIMENTAL
Intervention: RV5
Number of subjects: 4040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4040
Study: 25349227

Group type: EXPERIMENTAL
Intervention: Transseptal catheterization for atrial fibrillation ablation
Number of subjects: 13
Study: 23138396

Group type: EXPERIMENTAL
Intervention: N-acethyl-cysteine (NAC) 600 mg twice daily the day before and the day of the procedure plus 154 mmol NaHCO3 solution (B0) at a rate of 3 ml/kg/h from at least 2 h before the procedure and at 1 ml/kg/h during and for the next 6-12 h (BN group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: 154 mmol NaHCO3 solution (B0) at a rate of 3 ml/kg/h from at least 2 h before the procedure and at 1 ml/kg/h during and for the next 6-12 h (B0 group)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: N-acethyl-cysteine (NAC) as above plus 154 mmol NaCl solution at a rate of 3 ml/kg/h from at least 2 h before the procedure and at 1 ml/kg/h during and for the next 6-12 h (SN group)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: N-acethyl-cysteine (NAC)
Number of subjects: 123

Group type: COMPARATOR
Intervention: No NAC
Number of subjects: 123
Study: 21636073

Group type: EXPERIMENTAL
Intervention: Sixteen weeks of progressive resistance training
Number of subjects: 64
Study: 19002646

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using two diode laser probes (660 nm, 6.2 J/cm², 6 min, continuous wave; 890 nm, 1 J/cm², 10 min, 1,500 Hz)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (placebo treatment, similar procedure without irradiation)
Number of subjects: 16
Study: 16311275

Group type: EXPERIMENTAL
Intervention: 3H1
Number of subjects: 630

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study: 15638022

Group type: EXPERIMENTAL
Intervention: Snodgrass urethroplasty
Number of subjects: 79

Group type: COMPARATOR
Intervention: Mathieu urethroplasty
Number of subjects: 79
Study: 10786260

Group type: EXPERIMENTAL
Intervention: Pharmacist outreach program with academic detailing on ACE inhibitors and angiotensin II-receptor inhibitors for CHF.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (physicians not receiving the outreach program).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients treated with digoxin and furosemide identified as CHF patients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients treated with an ACE inhibitor for CHF.
Number of subjects: 0
Study: 9326126

Group type: EXPERIMENTAL
Intervention: Local anaesthetic
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anaesthetic
Number of subjects: 0
Study: 8353101

Group type: EXPERIMENTAL
Intervention: 5-FU + levamisole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-operative local chemotherapy (intraportal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-operative radiation therapy with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-FU + MeCCNU +/‐ oncovin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single agent systemic chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative radiation therapy
Number of subjects: 0
Study: 2874738

Group type: EXPERIMENTAL
Intervention: AC-DTP vaccine
Number of subjects: 60
Study: 30118241

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Exercise combined with vitamin C (EX + Vit.C)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 27
Study: 25721305

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 66
Study: 24916996

Group type: EXPERIMENTAL
Intervention: New sample of 800 cases after data rectification
Number of subjects: 800

Group type: COMPARATOR
Intervention: Initial sample of 840 cases from Multan
Number of subjects: 800
Study: 21538700

Group type: EXPERIMENTAL
Intervention: bihemispheric transcranial direct current stimulation and simultaneous physical/occupational therapy for five consecutive days
Number of subjects: 15
Study: 20541949

Group type: EXPERIMENTAL
Intervention: TachoSil®
Number of subjects: 299

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 299
Study: 18534326

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo group (sham acupuncture)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 16225490

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 20 mg
Number of subjects: 183

Group type: COMPARATOR
Intervention: Oral esomeprazole 40 mg
Number of subjects: 183

Group type: COMPARATOR
Intervention: Oral esomeprazole 20 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole
Number of subjects: 183

Group type: COMPARATOR
Intervention: Oral esomeprazole
Number of subjects: 183
Study: 12481473

Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study: 10407906

Group type: EXPERIMENTAL
Intervention: Fast rate of digit presentation (100 msec. interstimulus interval)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Slow rate of digit presentation (1,300 msec. interstimulus interval)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Immediate time estimation
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: List length of 25 digits
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: List length of 50 digits
Number of subjects: 139
Study: 7756468

Group type: EXPERIMENTAL
Intervention: Ritipenem acoxil (500 mg three times daily)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Norfloxacin (200 mg twice daily)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Ritipenem acoxil
Number of subjects: 281

Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 281
Study: 2144788

Group type: EXPERIMENTAL
Intervention: 0.18 mg/kg ondansetron (high dose)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg ondansetron (low dose)
Number of subjects: 36
Study: 7286585

Group type: EXPERIMENTAL
Intervention: Cabernet Sauvignon (mean ethanol concentration = 9500 mg/dl)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-alcohol Cabernet Sauvignon (mean ethanol concentration = 1312 mg/dl)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Wine (with solid food)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-alcohol wine (without solid food)
Number of subjects: 10
Study: 29071331

Group type: EXPERIMENTAL
Intervention: Dalcetrapib, 600 mg daily
Number of subjects: 4140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4140
Study: 26694846

Group type: EXPERIMENTAL
Intervention: 18‐wk supervised exercise program
Number of subjects: 33

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 33
Study: 24895566

Group type: EXPERIMENTAL
Intervention: Prior upper body exercise (4 sets of biceps curls)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No prior upper body exercise (control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Prior upper body exercise
Number of subjects: 11
Study: 22537990

Group type: EXPERIMENTAL
Intervention: Healive (one dose)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Havrix (one dose)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Healive (two doses)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Havrix (two doses)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Healive-Havrix (two doses)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Havrix-Healive (two doses)
Number of subjects: 303
Study: 20445430

Group type: EXPERIMENTAL
Intervention: Teaching intervention for ankle reflex examination skills
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 17566515

Group type: EXPERIMENTAL
Intervention: Glucan solution nasal spray
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study: 15683490

Group type: EXPERIMENTAL
Intervention: HRT (estradiol plus norethisterone acetate, n = 13)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ERT (estradiol, n = 14)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 40
Study: 11996634

Group type: COMPARATOR
Intervention: Newer antidepressant medications (including serotonergic antidepressants and buspirone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzodiazepines and tricyclic antidepressants (TCAs)
Number of subjects: 0
Study: 10488969

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU daily for 8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8730557

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy plus drug resistance modifying agents such as cyclosporins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0
Study: 1664629

Group type: EXPERIMENTAL
Intervention: 1% prilocaine plus sodium bicarbonate
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1% prilocaine
Number of subjects: 30
Study: 6861873

Group type: EXPERIMENTAL
Intervention: Controlled release (CR) formulation of indomethacin 75 mg (Indocid‐Retard) given once daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional 25 mg indomethacin capsule (Indocid) given 3 times daily
Number of subjects: 14
Study: 31730506

Group type: EXPERIMENTAL
Intervention: Community-based interventions (exercise, medication, nutritional management, improving safety of the local environment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Programs aimed at preventing hospital inpatient falls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital inpatient falls
Number of subjects: 0
Study: 29381666

Group type: EXPERIMENTAL
Intervention: CEE plus MPA (2.5 mg/d)
Number of subjects: 18015

Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/d)
Number of subjects: 18015

Group type: COMPARATOR
Intervention: Placebo for CEE plus MPA
Number of subjects: 18015

Group type: COMPARATOR
Intervention: Placebo for CEE
Number of subjects: 18015

Group type: EXPERIMENTAL
Intervention: CEE plus MPA (2.5 mg/d) postintervention
Number of subjects: 18015

Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/d) postintervention
Number of subjects: 18015
Study: 26786744

Group type: EXPERIMENTAL
Intervention: Active choice HIV test offers
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Opt-out HIV test offers
Number of subjects: 4800

Group type: COMPARATOR
Intervention: Opt-in HIV test offers
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: All arms (opt-in, active choice, opt-out)
Number of subjects: 4800
Study: 26039906

Group type: EXPERIMENTAL
Intervention: Low-cost glass ionomer cement (GIC)
Number of subjects: 437

Group type: COMPARATOR
Intervention: High-cost glass ionomer cement (GIC)
Number of subjects: 437
Study: 22318530

Group type: EXPERIMENTAL
Intervention: Ramadan‐intermittent‐fasting (RIF) during the second week of Ramadan (SWR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ramadan‐intermittent‐fasting (RIF) during the fourth week of Ramadan (ER)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Wingate test at 07:00 (morning)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Wingate test at 17:00 (evening) during Ramadan
Number of subjects: 10
Study: 19508679

Group type: COMPARATOR
Intervention: 0.1 mg rhTSH
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.3 mg rhTSH
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.9 mg rhTSH
Number of subjects: 9
Study: 18586811

Group type: EXPERIMENTAL
Intervention: Low-frequency electrical stimulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16043847

Group type: EXPERIMENTAL
Intervention: SITA-Standard (SS) visual field testing
Number of subjects: 243

Group type: COMPARATOR
Intervention: Full-threshold (FT) visual field testing
Number of subjects: 243
Study: 12417271

Group type: COMPARATOR
Intervention: LpE:A-I:A-II
Number of subjects: 2

Group type: COMPARATOR
Intervention: LpE:A-II
Number of subjects: 2

Group type: COMPARATOR
Intervention: LpE:A-I
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: LpE
Number of subjects: 2

Group type: COMPARATOR
Intervention: apoA-I on LpA-I:A-II
Number of subjects: 2

Group type: COMPARATOR
Intervention: apoA-I on LpA-I
Number of subjects: 2
Study: 10466902

Group type: EXPERIMENTAL
Intervention: Coaguchek monitor
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ProTime Microcoagulation System
Number of subjects: 30

Group type: COMPARATOR
Intervention: Survey preference for INR determination methods
Number of subjects: 30
Study: 7492829

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study: 1776335

Group type: EXPERIMENTAL
Intervention: Molsidomine (16 mg, slow-release formulation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6222987

Group type: EXPERIMENTAL
Intervention: All-RN model of nursing care delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Team model of nursing care delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modular model of nursing care delivery
Number of subjects: 0
Study: 31869756

Group type: EXPERIMENTAL
Intervention: Standardised medical (including psychiatric) care + cognitive behavioural therapy for dissociative seizures (part of the CODES trial)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Standardised medical (including psychiatric) care
Number of subjects: 698
Study: 30822478

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 110

Group type: COMPARATOR
Intervention: White Light (WL)
Number of subjects: 110
Study: 27998015

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 6051

Group type: COMPARATOR
Intervention: Al(OH)3 (control)
Number of subjects: 6051
Study: 25653009

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) exercise, 16 weeks, 60 minutes per session, three times a week
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no Tai Chi exercise)
Number of subjects: 27
Study: 24403284

Group type: EXPERIMENTAL
Intervention: Educational plan
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 174
Study: 22961514

Group type: EXPERIMENTAL
Intervention: TIPP (transinguinal preperitoneal) repair
Number of subjects: 302

Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 302
Study: 18404160

Group type: EXPERIMENTAL
Intervention: ALC group (29 eyes)
Number of subjects: 50

Group type: COMPARATOR
Intervention: MMC group (21 eyes)
Number of subjects: 50
Study: 17060331

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1 MAC
Number of subjects: 23

Group type: COMPARATOR
Intervention: Propofol 4 mug ml(‐1)
Number of subjects: 23
Study: 17765963

Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril and indapamide
Number of subjects: 11140
Study: 14747638

Group type: EXPERIMENTAL
Intervention: Stress condition (acute stress elicited by a standard speech task)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control condition (no acute stress)
Number of subjects: 59
Study: 10701625

Group type: EXPERIMENTAL
Intervention: 250 mg/ml (1250)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 300 mg/ml (1300)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 350 mg/ml (1350)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study: 9122857

Group type: EXPERIMENTAL
Intervention: microSelectron-HDR
Number of subjects: 45

Group type: COMPARATOR
Intervention: Selectron-MDR
Number of subjects: 45
Study: 8315152

Group type: EXPERIMENTAL
Intervention: Forward masker presented before the signal (louder tone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Forward masker presented before the standard (softer tone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forward masker presented in both intervals of a two-interval trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forward masker presented before the lower frequency tone
Number of subjects: 0